SCHECHTER JONATHAN 4

What Happened
Jonathan Schechter, a director of PharmaCyte Biotech, Inc. (PMCB), was granted 119,170 derivative awards reported as stock options on 2026-03-31. The awards are shown at $0.00 per share (no cash payment reported) and the filing lists the transaction as an award/grant (code A). The grant vests in full on the date of the issuer's next annual meeting of stockholders, subject to Mr. Schechter’s continued service.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-02.
• Transaction type: Grant/Award of derivative securities (options), Code A.
• Quantity and price: 119,170 options at $0.00 per share; cash paid = $0.
• Shares owned after transaction: Not reported in this filing.
• Footnote (F1): Options vest in full on the date of the issuer’s next annual meeting, subject to continued service.
• Timeliness: Filing appears on 2026-04-02; no late filing flag shown.

Context
This was a compensation award (option grant), not an open-market purchase or sale. Such grants do not immediately create tradable shares until options vest and are exercised; they are commonly used to align directors’ interests with shareholders. Watch for future Form 4s if/when options vest, are exercised, or resulting shares are sold.